Published online: December 3, 2009

Introduction {#sec1}
============

Adult hematopoiesis depends on rare multipotent bone marrow (BM)-resident hematopoietic stem cells (HSCs) ([@bib21]). HSCs may remain quiescent, self-renew, undergo apoptosis, or differentiate into multiple blood lineages. Tight regulation of these fates is essential to maintain the adult HSC pool, and studies in mice have revealed some of the key regulators of HSC maintenance. To identify novel regulators of adult HSC maintenance, we and others employed comparative global gene expression approaches. These studies identified the p300/CBP-binding transcriptional coactivator Cited2 as a candidate regulator of adult HSCs ([@bib8; @bib17; @bib32]), but functional validation remains to be performed.

*CITED2* mutations are found in patients with congenital heart disease ([@bib28]), lending clinical significance in trying to understand *CITED2* function. Cited2 physically interacts with the histone acetyltransferase p300/CBP ([@bib3]), coactivates DNA-binding transcription factors ([@bib2; @bib6; @bib7; @bib30]), and represses HIF-1-mediated transcription ([@bib3]). *Cited2* has oncogenic properties ([@bib29]) and controls proliferation of mouse embryonic fibroblasts (MEFs) via polycomb group genes *Bmi-1* and *Mel18* and the tumor suppressor *Ink4a/Arf* ([@bib10]). *Cited2* deletion in mice is embryonic lethal, causing multiple developmental defects ([@bib2; @bib31]), including impaired fetal liver hematopoiesis ([@bib5]). Severe fetal liver malformations ([@bib26]) precluded defining a cell-autonomous role for *Cited2* in HSC function and hematopoiesis, although these findings suggest a potential role for *Cited2* in fetal HSC regulation. In this study, we use a conditional knockout strategy to establish a requirement for *Cited2* in adult HSCs. Further, we demonstrate a role for *CITED2* in human hematopoiesis by RNA interference in CD34^+^ cord blood (CB) cells.

Results {#sec2}
=======

*Cited2* Is Essential for Sustaining Multilineage Hematopoiesis {#sec2.1}
---------------------------------------------------------------

*Cited2* expression analysis indicated that it is highly expressed in long-term HSCs (LT-HSCs; Lin^−^Sca-1^+^c-kit^+^(LSK)CD34^−^Flt3^−^ cells), less abundantly in short-term HSCs (ST-HSCs; LSKCD34^+^Flt3^−^ cells), and profoundly downregulated in lymphoid-primed multipotent progenitors (LMPPs; LSKCD34^+^Flt3^+^ cells) ([Figure 1](#fig1){ref-type="fig"}A). To investigate a functional requirement for *Cited2* in adult hematopoiesis, we generated *Cited2*^fl/fl^ *Mx1-Cre* conditional knockout mice ([@bib16]), in which treatment with poly(I)-poly(C) (pIpC) induces efficient gene deletion in hematopoietic cells ([@bib11]). We treated *Cited2*^fl/fl^ *Mx1-Cre* and *Cited2*^fl/fl^ mice with pIpC ([Figure 1](#fig1){ref-type="fig"}B) and refer to these as *Cited2*^Δ/Δ^ and *Cited2*^fl/fl^ mice, respectively. After Cre-mediated recombination, a *lacZ* expression cassette comes under the control of the endogenous *Cited2* promoter ([@bib16]), and efficient gene deletion was demonstrated by abundant lacZ expression in *Cited2*^Δ/Δ^ BM cells ([Figure S1](#app2){ref-type="sec"}A available online). Furthermore, *Cited2* mRNA was undetectable in *Cited2*^Δ/Δ^ BM cells ([Figure 1](#fig1){ref-type="fig"}C). Within 6 to 15 days after initiation of pIpC treatment, most *Cited2*^Δ/Δ^ mice became moribund and were sacrificed, in contrast to control mice, which survived normally ([Figure S1](#app2){ref-type="sec"}B). BM analysis revealed severely reduced cellularity in *Cited2*^Δ/Δ^ mice ([Figure 1](#fig1){ref-type="fig"}D) and strikingly reduced frequencies of mature myeloid (Mac-1^+^Gr-1^+^) and B-lymphoid (CD19^+^B220^+^) cells in *Cited2*^Δ/Δ^ BM, as compared to control mice ([Figure 1](#fig1){ref-type="fig"}E). Conditional loss of *Cited2* also reduced T cell frequencies ([Figure 1](#fig1){ref-type="fig"}E). These data support an essential role for *Cited2* in sustaining adult multilineage hematopoiesis.

*Mx1-Cre* mediates gene deletion in both hematopoietic and nonhematopoietic tissues ([@bib11]), so we assessed the contribution of *Cited2* deletion in nonhematopoietic tissues to morbidity. We transplanted wild-type (WT) BM cells into *Cited2*^fl/fl^ *Mx1-Cre* and *Cited2*^fl/fl^ mice, and 12 weeks after transplantation, recipients received pIpC. We observed no lethality in either cohort of mice ([Figure S1](#app2){ref-type="sec"}C), indicating that BM failure in *Cited2*^Δ/Δ^ mice is the primary cause of mortality.

*Cited2* Is Dispensable for the Maintenance of Committed Blood Lineages {#sec2.2}
-----------------------------------------------------------------------

The multilineage defects observed in *Cited2*^Δ/Δ^ mice could reflect a requirement for *Cited2* in the maintenance of committed hematopoietic lineages. To test this hypothesis, we used *Cd19-Cre*, *LysM-Cre*, and *Cd4-Cre* strains to delete *Cited2* in B cell, myeloid, and T cell lineages, respectively. *Cd19-Cre* efficiently excised *Cited2* in CD19^+^B220^+^ cells but did not affect their frequency in the BM ([Figure 2](#fig2){ref-type="fig"}A). Likewise, efficient deletion of *Cited2* in the myeloid compartment led to lacZ expression in the majority of Mac-1^+^Gr-1^+^ cells, but did not alter the frequency of these cells in the BM ([Figure 2](#fig2){ref-type="fig"}B). *Cd4-Cre* efficiently excised *Cited2* in T cells but did not change their frequency in the thymus ([Figure 2](#fig2){ref-type="fig"}C). Therefore, *Cited2* is expendable for the maintenance of these committed lineages.

*Cited2* Is Required for the Maintenance of Adult HSCs {#sec2.3}
------------------------------------------------------

Next, we addressed the impact of *Cited2* deletion on HSC and progenitor cell activity. In colony-forming cell (CFC) assays, *Cited2*^Δ/Δ^ BM cells failed to generate colonies in methylcellulose ([Figure 3](#fig3){ref-type="fig"}A). To evaluate HSC activity in vitro, we performed limiting dilution cobblestone area-forming cell (CAFC) assays and found that *Cited2*^Δ/Δ^ BM completely lacked CAFCs ([Figure 3](#fig3){ref-type="fig"}B). To assess HSC activity in vivo, we transplanted CD45.2^+^ BM cells from *Cited2*^Δ/Δ^ and *Cited2*^fl/fl^ control mice (with or without WT CD45.1^+^ BM competitors) into irradiated congenic CD45.1^+^ recipients. Without CD45.1^+^ BM competitors, *Cited2*^Δ/Δ^ BM cells did not rescue recipient mice from lethal irradiation (data not shown). Furthermore, CD45.2^+^ *Cited2*^Δ/Δ^ BM cells transplanted with CD45.1^+^ BM competitor cells did not contribute to multilineage hematopoiesis ([Figure 3](#fig3){ref-type="fig"}C). Immunophenotypic analysis of *Cited2*^Δ/Δ^ BM revealed a near complete loss of cells in the LSK compartment ([Figure 3](#fig3){ref-type="fig"}D) that contains LT-HSCs, ST-HSCs, and LMPPs. The frequency of Lin^−^Sca-1^−^c-Kit^+^ (LK) myeloid progenitor cells was also profoundly decreased in *Cited2*^Δ/Δ^ mice. To exclude the effects of pIpC-induced Cre-mediated toxicity on hematopoietic stem and progenitor cells (HSPCs), we compared the immunophenotypic and functional properties of HSPCs from *Cited2*^+/+^ *Mx1-Cre* and *Cited2*^fl/fl^ mice and found no apparent differences ([Figures S2](#app2){ref-type="sec"}A--S2D). These data indicate that pIpC-induced Cre activity does not phenocopy *Cited2* deletion in HSPCs.

The rapid kinetics of HSC loss upon acute deletion of *Cited2* suggest a survival defect. To test this, we deleted *Cited2* in cultured LSK cells and demonstrated that the rate of apoptosis was markedly increased in *Cited2*^Δ/Δ^ cells, as compared to WT cells ([Figure S2](#app2){ref-type="sec"}E). Thus, decreased survival of LSK cells underpins the multilineage BM failure observed in *Cited2*^Δ/Δ^ mice.

*Cited2* Functions in a Cell-Autonomous Manner in HSCs {#sec2.4}
------------------------------------------------------

To independently examine whether loss of *Cited2*^Δ/Δ^ HSCs is caused by *Cited2* deletion specifically in the hematopoietic system, we mixed CD45.2^+^ BM cells from untreated *Cited2*^fl/fl^ *Mx1-Cre* or *Cited2*^fl/fl^ mice with CD45.1^+^ WT BM competitor cells and transplanted them into irradiated recipients. Eight weeks after transplantation, the mice received pIpC and five days after the last dose the percentage of the donor-derived CD45.2^+^ cells was analyzed in the BM. The percentage of CD45.2^+^ *Cited2*^Δ/Δ^ cells in LSK and LK compartments was significantly reduced compared to CD45.2^+^ *Cited2*^fl/fl^ cells ([Figure 3](#fig3){ref-type="fig"}E). These data indicate a cell-autonomous requirement for *Cited2* in HSC maintenance.

*CITED2* Is a Regulator of Primitive Hematopoietic Cell Function in Human Cord Blood {#sec2.5}
------------------------------------------------------------------------------------

The high evolutionary conservation of Cited2 in mammals ([@bib3]) suggests a conserved role for Cited2 in HSC function. We generated a lentivirus expressing short-hairpin RNA (shRNA) targeting human *CITED2* ([Figures S3](#app2){ref-type="sec"}A--S3D) and performed assays to enumerate LTC-ICs, the most primitive human progenitors assessable in vitro. CB CD34^+^ cells transduced with shRNA and control lentiviruses were cocultured on stromal cells. *CITED2* knockdown in CD34^+^ cells led to a severe reduction in cellularity over time, compared to CD34^+^ cells transduced with a control lentivirus ([Figure S3](#app2){ref-type="sec"}E). Furthermore, *CITED2* knockdown in CD34^+^ cells strikingly impaired primitive hematopoietic cell activity, as judged by LTC-IC assays ([Figure 3](#fig3){ref-type="fig"}F). Thus, our data indicate that *CITED2* is a conserved regulator of primitive hematopoietic cell function in mammals. Furthermore, with this *Mx1-Cre*-independent model system, we corroborate the data obtained in our conditional mouse model.

Intact *Ink4a/Arf* and *Trp53* Are Required for the Loss of *Cited2*^Δ/Δ^ HSCs {#sec2.6}
------------------------------------------------------------------------------

We previously showed that *Cited2* null MEFs senesce prematurely and have increased levels of p16^Ink4a^ and p19^Arf^ ([@bib10]), whereas ectopic expression of *Cited2* represses *p16^Ink4a^* and *p19^Arf^*, enhancing MEF proliferation. Deletion of *Ink4a/Arf* or *Trp53* (encoding p53, a downstream target of p19^Arf^), rescued defective proliferation in *Cited2*^−/−^ MEFs ([Figure S4](#app2){ref-type="sec"}A; [@bib10]). *Ink4a/Arf* and *Trp53* are essential in maintaining HSC function ([@bib1]), so we hypothesized their involvement in the loss of *Cited2*^Δ/Δ^ HSCs. Consistent with this, *Cited2* deletion in LSK cells resulted in an increased expression of p19^Arf^ and p53 proteins and a p53 target gene *Cdkn1a* ([Figures S4](#app2){ref-type="sec"}B--S4D). Next, we generated *Cited2*^fl/fl^ *Mx1-Cre Trp53*^+/−^, *Cited2*^fl/fl^ *Mx1-Cre Trp53*^−/−^, *Cited2*^fl/fl^ *Mx1-Cre Ink4a/Arf* ^+/−^, and control mice and treated them with pIpC. Q-PCR confirmed that *Cited2* was not expressed in *Cited2*^Δ/Δ^ BM cells, regardless of *Ink4a/Arf* and *Trp53* status ([Figure S4](#app2){ref-type="sec"}E). Deletion of one *Ink4a/Arf* allele or one or two alleles of *Trp53* restored total BM cellularity in *Cited2*^Δ/Δ^ mice to the levels observed in *Cited2*^fl/fl^ control mice (Figures [4](#fig4){ref-type="fig"}A and [1](#fig1){ref-type="fig"}D). Ablation of one allele of *Trp53* also rescued B cell and myeloid development in *Cited2*^Δ/Δ^ BM ([Figure 4](#fig4){ref-type="fig"}B). Furthermore, deletion of one allele of *Ink4a/Arf* or one or two alleles of *Trp53* restored BM *Cited2*^Δ/Δ^ LSK cells ([Figure 4](#fig4){ref-type="fig"}C). BM cells from *Cited2*^Δ/Δ^ *Trp53*^+/−^, *Cited2*^Δ/Δ^ *Trp53*^−/−^, and *Cited2*^Δ/Δ^ *Ink4a/Arf* ^+/−^, but not *Cited2*^Δ/Δ^, mice efficiently generated multilineage colonies in methylcellulose ([Figure 4](#fig4){ref-type="fig"}D). After confirming that *Cited2*^Δ/Δ^ *Trp53*^+/−^, *Cited2*^Δ/Δ^ *Trp53*^−/−^, and *Cited2*^Δ/Δ^ *Ink4a/Arf* ^+/−^ cells from primary colonies lacked *Cited2* expression, we demonstrated efficient generation of secondary colonies (data not shown).

To examine whether HSCs lacking both *Cited2* and *Trp53* have long-term repopulating capacity, we transplanted *Cited2*^Δ/Δ^ *Trp53*^+/+^, *Cited2*^Δ/Δ^ *Trp53*^−/−^, and *Cited2*^fl/+^ *Trp53*^−/−^ total BM cells (mixed with WT support BM cells) into irradiated recipients and analyzed peripheral blood (PB) 16 weeks after transplantation. *Cited2*^Δ/Δ^ *Trp53*^+/+^ BM cells failed to repopulate recipients ([Figure 4](#fig4){ref-type="fig"}E), whereas BM cells lacking both *Cited2* and *Trp53* repopulated recipients to a similar extent as those lacking *Trp53* with intact *Cited2*. To corroborate this, we transplanted BM cells from untreated *Cited2*^fl/fl^ *Mx1-Cre Trp53*^+/+^ and *Cited2*^fl/fl^ *Mx1-Cre Trp53*^+/−^ mice into irradiated recipients ([Figure 4](#fig4){ref-type="fig"}F). After reconstitution, the recipients were treated with pIpC and analyzed 8 weeks after administration of the last dose. We measured the percentage of donor cell chimerism in PB nucleated cells or myeloid cells of recipients by using lacZ as a marker of *Cited2*-deficient cells. Whereas *Cited2*^Δ/Δ^ *Trp53*^+/+^ cells failed to sustain hematopoiesis, those lacking *Cited2* and one allele of *Trp53* showed significant donor-derived contribution ([Figure 4](#fig4){ref-type="fig"}G). Together, these data provide genetic evidence that the loss of HSCs in *Cited2*^Δ/Δ^ mice is, at least in part, mediated by *Ink4a/Arf* and *Trp53*.

Discussion {#sec3}
==========

In this report, we investigate the requirement for *Cited2* in adult HSCs maintenance and committed hematopoietic lineages. By using an inducible conditional knockout approach in adult mice, we demonstrate that *Cited2* deletion results in an acute loss of HSCs, at least in part via apoptosis, subsequently causing multilineage BM failure. Specific deletion of *Cited2* within the hematopoietic system demonstrates a cell-autonomous requirement for *Cited2* in maintaining adult HSC integrity, whereas deleting *Cited2* in committed lymphoid and myeloid lineages has no impact. Furthermore, *CITED2* knockdown in human CD34^+^CB reveals a conserved requirement for *Cited2* in HSC maintenance. Together, our data provide evidence that *Cited2* functions in a cell-autonomous manner to maintain HSCs.

Genetic evidence indicates that the tumor suppressors *Ink4a/Arf* and *Trp53* regulate multiple HSC fate decisions ([@bib1; @bib15; @bib18]). One function of p19^Arf^ is to stabilize p53 ([@bib23]), and the activation of the p19^Arf^-p53 pathway results in loss of HSCs ([@bib22]). We showed that loss of *Cited2* increased p19^Arf^ and p53 expression in the LSK compartment. Based on this observation, we used a genetic rescue approach to test whether *Ink4a/Arf* and *Trp53* are required for loss of HSCs lacking *Cited2*. Our results demonstrated that deletion of *Ink4a/Arf* or *Trp53* restored functionality of HSCs lacking *Cited2*, implying that *Cited2* maintains HSCs, at least in part, via *Ink4a/Arf* and *Trp53*. These data support the postulate that deletion of *Cited2* in HSCs results in activation of the p19^ARF^-p53 pathway and thereby leads to their loss.

It is of interest to relate Cited2 to other critical regulators of HSC maintenance. *Cited2* is required for *Bmi-1* expression in MEFs ([@bib10]) and myeloid progenitors ([@bib5]). *Bmi-1* maintains HSCs ([@bib14; @bib22]) and directly represses *Ink4a/Arf* ([@bib4]), whereas deletion of *Ink4a/Arf* ([@bib18]) or *Trp53* ([@bib1]) restores *Bmi-1*^−/−^ HSC function. Genetic evidence indicates distinct roles for *Bmi-1* and *Cited2* in HSC fate decisions. Whereas *Bmi-1* mediates HSC self-renewal, our results are compatible with a requirement for *Cited2* in HSC survival. In agreement with this, acute *Cited2* deletion in HSCs does not affect the expression of *Bmi-1* (data not shown), suggesting that downregulation of *Bmi-1* expression is not responsible for the loss of *Cited2*^Δ/Δ^ HSCs. However, this does not exclude the possibility that *Cited2* controls *Bmi-1* in other contexts in HSCs. Conditional deletion of *Cited2* generates a stem cell phenotype reminiscent of conditional inactivation of *Tel/Etv6* and *Mcl-1* ([@bib9; @bib20]). Like *Tel/Etv6* ([@bib9]), *Cited2* appears to be selectively required for HSC maintenance, but dispensable for mature lineages. Mcl-1, however, also plays critical roles in mature T and B cell survival ([@bib19]), revealing a broader spectrum of hematopoietic function than Cited2. Conditional deletion of *Apc* and combined deficiency of *c-Myc* and *N-Myc* (but not ablation of *N-Myc* alone) results in loss of HSCs ([@bib13; @bib25]). Although the expression of *Apc* and *c-Myc* is unaltered in *Cited2*-deficient HSCs, the expression of *N-myc* is decreased (data not shown). Although this observation alone does not explain the loss of *Cited2*-deficient HSCs, N-Myc may mediate some functions of Cited2 in HSCs. Finally, Cited2 binds p300 and its paralog CBP ([@bib3]). Although *Cbp* is essential for adult HSC maintenance, *p300* appears dispensable for HSC maintenance but required for multilineage hematopoietic differentiation ([@bib12; @bib27]). It will be of interest to clarify the roles of Cbp-Cited2 and p300-Cited2 interactions in adult HSC maintenance and hematopoiesis, and the relationship between Cited2 and other critical stem cell regulators remains an open question meriting future investigation.

In conclusion, we provide genetic evidence that *Cited2* is an essential and cell-autonomous regulator of adult mammalian HSC maintenance. Our data, together with the sufficiency of Cited2 to maintain undifferentiated embryonic stem cells ([@bib24]), suggest that it is a critical master regulator of stem cell fate. Understanding Cited2 functions at the molecular level will offer insights into the similarities and differences in the transcriptional circuitry of embryonic and somatic stem cells.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

We backcrossed *Cited2*^fl/fl^ and *Cited2*^+/−^ mice ([@bib2; @bib16]) to C57BL/6J for ten generations to generate coisogenic mice. *Mx1-Cre*, *Cd19-Cre*, and *LysM-Cre* mice were purchased from the Jackson Laboratory. *Cd4-Cre* mice were purchased from Taconic. *Ink4a/Arf* ^+/−^ and *Trp53*^+/−^ mice were obtained from B. Hassan and M. van Lohuizen, respectively. All experiments on animals were performed under UK Home Office authorization.

Administration of pIpC {#sec4.2}
----------------------

8- to 12-week-old mice received five to six intraperitoneal injections of pIpC (GE Healthcare; 0.2--0.3 mg per dose) every alternate day. Deletion efficiency was determined by Q-PCR or lacZ expression analysis (via a FluoReporter lacZ Flow Cytometry Kit, Invitrogen).

Murine CAFC Assay {#sec4.3}
-----------------

Stromal layers were prepared from the BM of C57BL/6J mice, irradiated at 15 Gy, and subcultured in 96-well flat-bottom plates at a density of 2 × 10^4^ cells per well. After 1 to 7 days, cultures were seeded at 2-fold dilutions (2.9 × 10^5^−18,125 per well) of nucleated BM cells from each genotype. CAFCs were scored at week 5.

CFC Assays {#sec4.4}
----------

H4434 and M3434 media (StemCell Technologies) were used to enumerate human and mouse colony-forming cells, respectively. Two replicates were used per group in each experiment. Colonies were tallied at day 10--14.

Q-PCR {#sec4.5}
-----

RNA extraction and Q-PCR reactions were performed as previously described ([@bib17]). For specific TaqMan Assays-on-Demand probes used, see [Supplemental Experimental Procedures](#app2){ref-type="sec"}. Reactions were run on an Applied Biosystems 7500 Fast Real-Time PCR System in normal mode for 50 cycles. All experiments were performed in triplicate. Differences in input cDNA were normalized with a combination of *Hprt*, *Gapdh*, *Actb, Ubc*, and *B2m* expression with qBase 1.3.5 software (<http://medgen.ugent.be/qbase/>).

Lentiviral Transductions {#sec4.6}
------------------------

*CITED2* shRNA was subcloned from the pLKO.1 puro vector (Open Biosystems) into the pLKO.1 GFP vector (gift from J. Larsson). Lentivirus production and transduction of human CD34^+^ CB cells are described in [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Human Long-Term Cultures on Stroma and LTC-IC Assays {#sec4.7}
----------------------------------------------------

CB CD34^+^ cells (StemCell Technologies) were isolated by MiniMACS (Miltenyi Biotec) selection. After transduction, 3 × 10^4^ cells were cultured on MS5 stromal cells in Long-Term Culture medium (see [Supplemental Experimental Procedures](#app2){ref-type="sec"}). Cultures were demidepopulated weekly for analysis. LTC-IC numbers were enumerated by overlaying MS5 stromal cocultures at week 5 with H4434 medium, followed by counting colonies 2 weeks later.

FACS {#sec4.8}
----

All samples were analyzed on a CyAn ADP flow cytometer (Dako). Sorts were performed on FACSAriaIIu (BD) or MoFlow (Dako) cell sorters. Antibodies are described in [Supplemental Experimental Procedures](#app2){ref-type="sec"}.

Competitive Repopulation Assay {#sec4.9}
------------------------------

CD45.2^+^ test donor BM cells were mixed with CD45.1^+^ competitor BM cells in a 1:1 ratio and injected intravenously into lethally irradiated (9 Gy) B6.SJL CD45.1^+^ recipients. The competitor cell number was 5 × 10^5^ cells in all experiments.

Statistical Analysis {#sec4.10}
--------------------

Statistical significance was determined via two-tailed Student\'s t tests assuming unequal variance.

Supplemental Data {#app2}
=================

Document S1. Supplemental Experimental Procedures and Four Figures
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Supplemental Data include Supplemental Experimental Procedures and four figures and can be found with this article online at <http://www.cell.com/cell-stem-cell/supplemental/S1934-5909(09)00574-8>.

![Conditional Deletion of *Cited2* Results in Multilineage Bone Marrow Failure\
(A) Relative expression of *Cited2* mRNA in LT-HSC, ST-HSC, and LMPP populations sorted from WT C57BL/6J mice. Data are mean ± SEM (n = 3).\
(B) *Cited2*^fl/fl^*Mx1-Cre* and *Cited2*^fl/fl^ mice received six injections of pIpC on alternate days and analyzed 5 days after the last injection.\
(C) Relative expression of *Cited2* mRNA in total BM cells from *Cited2*^Δ/Δ^ and control mice (mean ± SEM; n = 3).\
(D) Total number of BM nucleated cells obtained from two tibias and two femurs of *Cited2*^Δ/Δ^ and control mice. The results are presented as mean number of cells ± SD (n = 5). ^∗^p \< 0.0001.\
(E) Top and middle: Frequencies of B-lymphoid and myeloid cells, respectively, in BM from *Cited2*^Δ/Δ^ and control mice. Bottom: FACS plot showing CD4 and CD8 staining in thymi from *Cited2*^Δ/Δ^ and control mice. Data are shown as mean frequency ± SD (n = 3).](gr1){#fig1}

![*Cited2* Is Dispensable for the Maintenance of Mature Lymphoid and Myeloid Lineages\
(A) Left: FACS plots showing CD19 and B220 staining of BM cells obtained from *Cited2*^+/+^*Cd19-Cre*^+/−^ and *Cited2*^fl/−^*Cd19-Cre*^+/−^ mice. Results from representative animals are shown (n = 3). Right: Relative expression of *Cited2* mRNA in CD19^+^B220^+^ cells sorted from peripheral blood (PB) of *Cited2*^+/+^*Cd19-Cre*^+/−^ and *Cited2*^fl/−^*Cd19-Cre*^+/−^ mice. Data are mean ± SEM (n = 3).\
(B) Left: FACS plot showing Mac-1 and Gr-1 staining of BM cells obtained from *Cited2*^fl/+^*LyzM-Cre*^+/−^ and *Cited2*^fl/−^*LyzM-Cre*^+/−^ mice. Data are shown as mean frequency ± SD (n = 3). Right: LacZ staining of BM Mac-1^+^Gr-1^+^ cells from *Cited2*^fl/+^*LyzM-Cre*^+/−^ and *Cited2*^fl/−^*LyzM-Cre*^+/−^ mice.\
(C) Left: FACS plots showing distribution of T cell subsets in the thymi of *Cited2*^fl/fl^ and *Cited2*^fl/fl^*Cd4-Cre* mice. Data are shown as mean frequency ± SD (n = 3). Right: Relative expression of *Cited2* mRNA in CD4^+^ and CD8^+^ cells sorted from PB of *Cited2*^fl/fl^ and *Cited2*^fl/fl^*Cd4-Cre* mice. Data are mean ± SEM (n = 3).](gr2){#fig2}

![*Cited2* Maintains HSCs in a Cell-Autonomous Manner\
*Cited2*^fl/fl^*Mx1-Cre* and control mice were treated with pIpC as shown in [Figure 1](#fig1){ref-type="fig"}B.\
(A) CFC assay performed on total BM cells from *Cited2*^Δ/Δ^ and control mice. The graph shows the mean number of CFC colonies ± SD counted on day 10 (n = 3 per group).\
(B) CAFC assay. The graph shows the mean number of cobblestone areas ± SEM counted at week 5 (n = 3).\
(C) Competitive repopulation assay. CD45.2^+^ BM cells from *Cited2*^Δ/Δ^ or control mice were mixed with CD45.1^+^ WT competitor BM cells and transplanted into irradiated CD45.1^+^ WT recipients. After 16 weeks, the contribution of CD45.2^+^ cells was analyzed. Data are mean percentage of CD45.2^+^ cells in PB of recipient mice ± SD (n = 6 per group).\
(D) Frequencies of the BM LSK and Lin^−^Sca-1^−^c-Kit^+^ (LK) cells from *Cited2*^Δ/Δ^, *Cited2*^+/Δ^, and *Cited2*^fl/fl^ control mice. The data are representative of four independent experiments.\
(E) BM cells from untreated *Cited2*^fl/fl^*Mx1-Cre* and *Cited2*^fl/fl^ mice were mixed with CD45.1^+^ WT competitive BM and transplanted into irradiated recipients. Eight weeks after tansplantation, the mice were treated with five doses of pIpC. Five days after last pIpC administration, the percentage of test CD45.2^+^ cells was measured in BM LSK and LK compartments. Data are mean ± SD (n = 3). ^∗^p \< 0.001; ^∗∗^p \< 0.0002.\
(F) LTC-IC assay. Human CD34^+^ CB cells transduced with shRNA and control lentiviruses were cocultured with MS5 stromal cells. After 5 weeks, medium was replaced with complete methylcellulose. The graph shows the mean percentage of GFP^+^ LTC-IC colonies in cultures ± SD (n = 2) scored 2 weeks after adding methylcellulose.](gr3){#fig3}

![Genetic Deletion of *Trp53* or *Ink4a/Arf* Restores HSC Functions and Rescues Bone Marrow Failure in *Cited2*^Δ/Δ^ Mice\
Mice of indicated genotypes were treated with pIpC.\
(A) Total BM cellularity from two tibias and two femurs. The results are presented as mean number of cells ± SD (n = 3 per genotype). ^∗^p \< 0.002 versus remaining genotypes.\
(B) Graphs show total number of BM CD19^+^B220^+^ cells (B cells) and Mac-1^+^Gr-1^+^ cells (myeloid cells) in two tibias and two femurs per mouse. Mean values ± SD (n = 4). ^∗^p \< 0.005 versus remaining genotypes.\
(C) Frequencies of the BM LSK cells from mice of indicated genotypes. FACS plots are representative of three independent experiments.\
(D) CFC assay. Nucleated BM cells were plated in methylcellulose medium. Cultures were assessed on day 10 for granulocyte (CFC-G), macrophage (CFC-M), granulocyte-macrophage (CFC-GM), erythroid (E), and mixed (Mix) colony formation. The data are representative of three independent experiments and are shown as the mean ± SD (n = 2 mice per genotype).\
(E) Contribution of donor cells from *Cited2*^fl/+^*Trp53*^−/−^, *Cited2*^Δ/Δ^*Trp53*^+/+^, and *Cited2*^Δ/Δ^*Trp53*^−/−^ mice to the myeloid compartment of PB 16 weeks after transplantation. BM cells from mice of the indicated genotypes were mixed with support WT BM cells and transplanted into irradiated recipients. The graph shows the mean (±SD) percentage of CD45.2^+^ cells in myeloid compartment of recipient mice (n = 3 per group). ^∗^p \< 0.0003 versus remaining genotypes.\
(F) Schematic of experimental design.\
(G) Contribution of donor cells of the indicated genotypes to PB. Percentage of lacZ^+^ donor cells was analyzed by flow cytometry in total PB mononuclear compartment and myeloid (Mac-1^+^Gr-1^+^) compartment of recipients (n = 5 per group). ^∗^p \< 0.002; ^∗∗^p \< 0.00008.](gr4){#fig4}
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